Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bianca D Santomasso

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Neuro-Oncology|August 22, 2025
Multicenter basket trial for Central Nervous System tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningiomaThomas J Kaley, Christian Grommes, Elizabeth Coffee, et al.
Blood Advances|February 22, 2020
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementMartina Pennisi, Tania Jain, Bianca D Santomasso, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsDaniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.
Blood Cancer Journal|February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesAdam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Blood Cancer Journal|November 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, et al.
Haematologica|February 22, 2020
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphomaRichard J Lin, Stephanie M Lobaugh, Martina Pennisi, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Neuro-Oncology|August 22, 2025
Multicenter basket trial for Central Nervous System tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningiomaThomas J Kaley, Christian Grommes, Elizabeth Coffee, et al.
Blood Advances|February 22, 2020
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementMartina Pennisi, Tania Jain, Bianca D Santomasso, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
Journal for Immunotherapy of Cancer|June 26, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJulie R Brahmer, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsDaniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 25, 2025
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal MetastasesMonica F Chen, Jake June-Koo Lee, Noura J Choudhury, et al.
Blood Cancer Journal|February 25, 2022
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesAdam D Cohen, Samir Parekh, Bianca D Santomasso, et al.
Blood Cancer Journal|November 26, 2025
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4Paula Rodríguez-Otero, Surbhi Sidana, Mathilde Kouwenhoven, et al.
Haematologica|February 22, 2020
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphomaRichard J Lin, Stephanie M Lobaugh, Martina Pennisi, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Pageof 5